Drug
Cv9103
Cv9103: highest development phase Phase 1/2, developed by CureVac. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- CureVac
Trials
| Drug | Phase | Indication |
|---|---|---|
| CV9103 NCT00831467 | Phase 1/2 | Hormonal Refractory Prostate Cancer |
| CV9103 NCT00906243 | Phase 1/2 | Hormone Refractory Prostate Cancer |
Latest
No recent events.
Follow Cv9103 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.